Adial Pharmaceuticals, Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
Adial Pharmaceuticals, Inc. (ADIL) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$7.98 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-05
- Adial Pharmaceuticals, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$7.98M.
- Adial Pharmaceuticals, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$13.20M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | -$7.98M 10-K · filed 2026-03-05 |
| 2024-12-31 | -$13.20M 10-K · filed 2026-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |